This website is intended for Medical Professionals only. By using this site you confirm that you are a healthcare professional.

News
Hormone therapy may increase cardiovascular ... Patients receiving hormone therapy as part of their ... (20 Feb 2019)
Avoiding Selfie Elbow, Texting Thumb Specialists are seeing more and more repetitive stress injuries ... (20 Feb 2019)
Adolescent Female Blood Donors At Risk For ... New public health measures could help protect this vulnerable ... (20 Feb 2019)
Lupus Strongly Linked to Imbalances in Gut ... The disease systemic lupus erythematosus (SLE) — marked by the ... (20 Feb 2019)
Study Finds Upsurge in ‘Active Surveillance’ ... Many men with low-risk prostate cancer who most likely ... (12 Feb 2019)
Friday, 13 July 2018 22:12

Valsartan: Updated list of potentially impacted products Featured

Rate this item
(0 votes)

The Superintendent of Public Health has issued an updated list of products with the active substance valsartan that may be potentially impacted by the N-nitrosodimethylamine (NDMA) impurity.

 

 

 

It is important to note that treatment should not be stopped until the patient has been prescribed an alternative. The health risk of discontinuing this medicine is higher than any potential risk presented by the impurity. At present there is no evidence that the impurity in some stocks of valsartan has caused any harm to patients. Further updates will be provided as more information becomes available.

 

Read 433 times

Latest news

Highlights

Join

Connect with other Medical Professionals on fb in a closed facebook group

Login

Top
We use cookies to improve our website. By continuing to use this website, you are giving consent to cookies being used. More details…